Stoke Therapeutics, Inc. Impairment of Long-Lived Assets Held-for-use
Stoke Therapeutics, Inc. (STOK) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2026-03-16
- Stoke Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2025 was $0.00.
- Stoke Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2024 was $0.00.
- Stoke Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2023 was $0.00.
- Stoke Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2022 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-16 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-16 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-18 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-25 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-06 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-10 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-09 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |